Clinical Hospital
Resume:
CURRICULUM VITAE JEFFREY A. GREEN
PERSONAL INFORMATION
Address: Residence - 2568 Eaton Road
University Heights, Ohio
44118
Telephone: Residence - 216-***-****
Office - 216-***-****
Licensure: Registered Pharmacist
Indiana by Examination #14299
Ohio by Reciprocity #03-31-4637
EMPLOYMENT HISTORY
November, 2009 - Present Senior Vice President, Clinical Development,
CCO Technology, Ltd., Cleveland, Ohio
. Responsible for the establishment of the Company's Nutraceutical
Development Strategy
. Major contributor to the preclinical and clinical development programs
creating the foundation for scientific expansion of the product and
accompanying IND submission
. Established marketing channel alliances and relationships for product
dissemination
April, 1999 - January 2009 Founder, Chairman & Chief Executive Officer,
DATATRAK International, Inc., Cleveland, Ohio
. Established the DATATRAK concept for the use of Electronic Data Capture
(EDC) in clinical trials in 1995
. Led the Company through the acquisition of current software product from
EDS-Germany
. From 1995 to Present led and funded the Company through the developing
EDC market into the premier, worldwide Application Service Provider (ASP)
. Developed the Data Item concept for EDC software licensing
. Created a popular Technology Transfer Initiative for empowerment of
clients in the use of DATATRAK EDC( in clinical trials
1992 - April, '99 Founder, President & Chief Executive Officer,
Collaborative Clinical Research, Inc., Cleveland, Ohio
. Developed the operational and economic concepts behind the
formation of one of the first site management
organizations, Collaborative Clinical Research, Inc.
. Collectively secured a total of $5 M of venture financing
in two different rounds in 1992 and 1994 for the
establishment and growth of Collaborative as an
entrepreneurial startup
. Directed the growth of Collaborative from a single site
operation in 1991 to over 550 Affiliated Sites by 1997
. Directed the acquisition of two wholly-owned clinical
research sites, namely, GFI Pharmaceuticals and Walker
Clinical Evaluations in 1996
. Founded a wholly-owned subsidiary of Collaborative called
DataTRAK, Inc. which was established to create a worldwide
service offering for the pharmaceutical industry related to
electronic data capture
. In 1996 lead an initial public offering of Collaborative
raising $46 M
92. Assistant Professor of Medicine & Radiology - Case Western
Reserve University School of Medicine, Cleveland, Ohio
. Founded, developed, and directed a clinical pharmacology
research program within the school of medicine
. Became a nationally recognized as an investigator in the
area of cardiovascular clinical pharmacology and in the use
of PET scanning as a tool in the drug development process
. Served as either Principal Investigator or Administrative
Director on more than 90 individual clinical research
projects during an 8 year period of time
. Authored over 90 abstracts and papers and have been an
invited speaker at more than 150 regional and national
research and professional society meetings
. Recipient in 1988 of the McKeen Cattell Distinguished
Achievement Award for Scientific Excellence and Literary
Presentation given by the American College of Clinical
Pharmacology
84. Clinical Pharmacist, Cardiology/Drug Information -
Department of Pharmacy, University Hospitals of Cleveland,
Cleveland, Ohio
. Served as clinical pharmacology consultant to both the
Coronary Care Unit/Division of Cardiology and the Formulary
Review Committee at the University Hospitals of Cleveland
. Opportunities and growth of this initial position led to
the development of an independent clinical research program
in the school of medicine
EDUCATION
Purdue University School of Pharmacy and Pharmacal Sciences, 1974-79.
Awarded Bachelor of Science Degree, May 1979
University of Texas at Austin and the University of Texas Health Science
Center at San Antonio Clinical Pharmacy Program, 1979-82. Awarded Doctor
of Pharmacy Degree, May 1982
Specialty Residency in Clinical Pharmacokinetics, University of Texas
Health Science Center at San Antonio, Clinical Pharmacy Program, 1981-82
ACADEMIC APPOINTMENT HISTORY
Adjunct Assistant Professor of Clinical Pharmacy, University of Toledo
College of Pharmacy, August 1982 - June 1984
Clinical Instructor, School of Medicine, Case Western Reserve University,
March 1984 - June 1984
Senior Instructor, School of Medicine, Case Western Reserve University,
July 1984 - June 1987
Clinical Pharmacist, Division of Cardiology, University Hospitals of
Cleveland, July 1984 - June 1992
Assistant Professor of Medicine, Case Western Reserve University School of
Medicine, July 1987 - June 1992
Head, Pharmaceutical Product Development, Positron Emission Tomography
Facility, University Hospitals of Cleveland, July 1987 - June 1992
Assistant Professor of Radiology/Nuclear Medicine, Case Western Reserve
University School of Medicine, July 1988 - June 1992
Adjunct Associate Professor of Clinical Pharmacy, Ohio Northern University
College of Pharmacy, March 1989 - 92
Assistant Director, Positron Emission Tomography Facility, University
Hospitals of Cleveland/Case Western Reserve University, July 1989 - June
1992
Adjunct Associate Professor of Pharmacy Practice, School of Pharmacy, State
University of New York at Buffalo, 1991 - June 1992
HONORS AND AWARDS
Phi Eta Sigma Freshman Honorary, Purdue University, April 1975
Smith Kline & French Award for Superior Achievement in Clinical Pharmacy,
Purdue University School of Pharmacy and Pharmacal Sciences, May 1979
Roche Hospital Pharmacy Research Award, December 1983
American College of Clinical Pharmacy Research Institute Award, June 1984
American Heart Association Grant, Northeast Ohio Affiliate, December 1985
Ohio Society of Hospital Pharmacists Research Award, presented to the
Cardiovascular Clinical Pharmacology Research Program, May 1986
American Society of Hospital Pharmacists Research and Education Foundation
Demonstration Project Grant, July 1987
McKeen Cattell Memorial Distinguished Achievement Award in recognition of
excellence in Pharmacological Research and Literary Presentation in the
Journal of Clinical Pharmacology, presented by the American College of
Clinical Pharmacology at the 1988 Annual Meeting, Orlando, FL, October 31,
1988
Elected Fellow, American College of Clinical Pharmacology, March 1989
Nominated as a candidate for a Fellow of the American College of Clinical
Pharmacy, December 1989
Nominated as a member of the CardioRenal Section, FDA Drug Advisory Panel,
October 1990
Recipient of an Innovation Award for the development of Collaborative
Clinical Research, given by Enterprise Development, Cleveland, April 1996
Entrepreneur of the Year Award, Northeast Region, from Ernst & Young,
Cleveland, Ohio, June 2005.
PHARMACY PRACTICE EXPERIENCE
Pre-Baccalaureate: Pharmacy Intern, Brokaw Hospital Pharmacy
Normal, Illinois 1976-79
Post-Baccalaureate: Resident, Bexar County Hospital
San Antonio, Texas 1979-82
Clinical Pharmacist in Cardiology/Drug Information
Department of Pharmacy Services
University Hospitals of Cleveland
Cleveland, Ohio 1982-84
ADMINISTRATIVE EXPERIENCE
Class Coordinator for first year Pharm.D. Residents, Doctor of Pharmacy
Program, University of Texas Health Science Center, San Antonio, 1979
Student Member, Graduate Faculty Council, University of Texas Health
Science Center, San Antonio, 1981-82
Member, Formulary Review Subcommittee, Department of Pharmacy Services,
University Hospitals of Cleveland, Cleveland, July 1982 - June 1984
Member, Pharmacy & Therapeutics Committee, University Hospitals of
Cleveland, Cleveland, July 1982 - June 1984
Co-Director of the Cardiovascular Clinical Pharmacology Research Program,
1984 -92
Preceptor, Cardiovascular Clinical Pharmacology Research Fellowship, 1986 -
92
Member, Program Committee, American College of Clinical Pharmacy Regional
Symposium on Controversies in Critical Care Therapeutics, Cleveland, 1987
Member, Program Committee, American College of Clinical Pharmacy Eighth
Annual Meeting, 1987
Panel Member, Cardiovascular Review Section, Pharmacy & Therapeutics
Committee, University Hospitals of Cleveland, Cleveland, 1987 - 92
Participant, Task Force on Developing Cardiovascular Research, Division of
Cardiology, University Hospitals of Cleveland and Case Western Reserve
University School of Medicine, 1987
Initiated and organized an Exhibitor's Theatre Program at the American
Society of Hospital Pharmacists Midyear Clinical Meeting pertaining to
Pharmacist Involvement in Pharmacoepidemiology and Thrombolytic Therapy,
Dallas, December, 1988
Preceptor, Clinical Cardiology rotation, State University of New York at
Buffalo School of Pharmacy, 1989 - 92
Conceived of an funded a national seminar entitled, "Pharmacist Involvement
in Clinical Research: Corporate, Governmental, and Regulatory
Perspectives", program included a lecture from a previous FDA Commissioner,
Dr. Alexander Schmidt, Cleveland, 1989
Assistant Director, Positron Emission Tomography Facility, University
Hospitals of Cleveland, July 1989 - June 1992
Consultant, Gliatech Corporation, 1990
Founder, President & Chief Executive Officer, Collaborative Clinical
Research, Inc., 1991 - Present
Founder, President & Chief Executive Officer, DATATRAK International, Inc.,
1995-Present
MEDICAL SCHOOL SERVICE - CASE WESTERN RESERVE UNIVERSITY
Preceptor, Cardiovascular Clinical Pharmacology Elective, Case Western
Reserve University School of Medicine, 1984 - 92
Preceptor, Summer Experience in Cardiology and Clinical Pharmacology
Research, Case Western Reserve University School of Medicine, 1986 - 92
Faculty, Principles of autonomic pharmacology, cat laboratory for second
year medical students, 1984 - 7
Phase I Cardiovascular Committee Lecture, "Cardiovascular Clinical
Pharmacology", 1990 - 92
PAST MEMBERSHIPS IN PROFESSIONAL SOCIETIES
American Society of Hospital Pharmacists
American College of Clinical Pharmacy
American Society of Clinical Pharmacology & Therapeutics
American Pharmaceutical Association
American Heart Association, Northeast Ohio Affiliate
Ohio State Pharmaceutical Association
American College of Clinical Pharmacology
Society of Critical Care Medicine
Institute for Clinical Positron Emission Tomography
PROFESSIONAL SERVICE
Member, Editorial Board, Cardiovascular Section, Drug Intelligence &
Clinical Pharmacy, 1985 - 88
Reviewer, American Heart Association, Northeast Ohio Affiliate, 1984
Reviewer, American Cancer Society, Ohio Division, 1985
Reviewer, Drugs in the elderly, Cleveland Foundation and the Division of
Pediatric Clinical Pharmacology and Critical Care, 1985
Reviewer, American Journal of Hospital Pharmacy, 1985 - 90
Consultant, NIH Multicenter Investigation - Cardiac Arrhythmia Suppression
Trial, University Hospitals of Cleveland and Case Western Reserve
University School of Medicine, Albert Waldo, MD, Principal Investigator,
1987
Chairman, Constitution and Bylaws Committee, American College of Clinical
Pharmacy, 1987 - 88
Reviewer, Pharmacotherapy, 1988 - 91
Abstract Reviewer for Annual Meetings, Cardiovascular Section, American
College of Clinical Pharmacy, 1986 - 90
Planning Committee Member, American College of Clinical Pharmacy Traveling
Symposium on Coronary Artery Disease, 1988
Reviewer, American Society of Hospital Pharmacists Clinical Research Forum,
1985 - 90
Reviewer, Clinical Pharmacy, 1986 - 90
Advisory Board, Research Digest in Vascular Disease, 1988 - 90
Nominated as a panel member of the Cardiovascular Section - "Clinical
Indicators of Quality" for the Joint Commission on Accreditation of Health
Care Organizations, April, 1988
Planning Committee, Legal Liability Question & Answer Session, American
College of Clinical Pharmacy 9th Annual Meeting, Philadelphia, 1988
Consultant to Abbott, Searle, and Parke-Davis Pharmaceuticals regarding FDA
requirement for Positron Emission Tomography studies with quinolone
antibiotics, 1989 - 91
Consultant, American Heart Association Application, "Perfusion & Metabolic
Imaging Pre- & Post-Coronary Bypass Surgery", David Joyce, MD, Principal
Investigator, October, 1988
Consultant, American Heart Association Application, "Comparison of Oxygen-
15 Labeled Water and Butanol for Myocardial Blood Flow in Pigs", Mark
Berridge, PhD, Principal Investigator, October, 1988
Reviewer, American College of Clinical Pharmacy Research Institute, 1988 -
92
Reviewer, American Hospital Formulary Service, 1988
Reviewer, American Pharmacy, 1988 - 90
Reviewer, Hospital Formulary, 1989 - 92
Reviewer, Chest, 1988 - 90
Elected, Member-at-Large Clinical Sciences Section, Academy of
Pharmaceutical Research and Science, American Pharmaceutical Association,
Washington, D.C., November, 1989
Reviewer, Elsevier Science Publishing Company, Inc., (Textbook proposal),
1989
Subspecialty Advisor in Cardiovascular Disease & Pharmacotherapy at the
Career Consultation Session, American Society of Hospital Pharmacists
Midyear Clinical Meeting, December, 1989
Policy Committee, Academy of Pharmaceutical Research & Science, Clinical
Sciences Section, American Pharmaceutical Association, 1990 - 91
Member, Board of Trustees of the American College of Clinical Pharmacy
Research Institute, 1990 - 92
Clinical Research Policy Advisory Committee, Department of Medicine, Case
Western Reserve University, 1990
Editorial Board, Transgenica: The Journal of Clinical Biotechnology, 1992
Reviewer, Antimicrobial Agents & Chemotherapy, (PET Quinolone
investigations), 1990
Reviewer, Model State Pharmacy Practice Act and Model Regulations, National
Association of Boards of Pharmacy, October, 1990
Contributor, Heart Failure Section, Pharmacotherapy Self-Assessment
Program, to be used in preparation for pharmacotherapy certification by the
American College of Clinical Pharmacy, October, 1990
Fellowship Selection Committee for the Cardiovascular Drug Therapy
Fellowship, American Society of Hospital Pharmacists Research & Education
Foundation, 1991
Member, Expert Advisory Panel on Cardiovascular & Renal Drugs, USP General
Committee of Revision, 1990 - 92
Member, Abstracts & Awards Committee, Pharmacology Section of the American
Society of Critical Care Medicine, 1991
Elected, Member-at-Large of the Ohio Chapter of the American College of
Clinical Pharmacology, 1989
Faculty Member, Vascular Surgery Advisory Board, December, 1991
SIGNIFICANT ACCOMPLISHMENTS
Appointed as a full-time faculty member of Case Western Reserve University
School of Medicine at the age of 28. Occurred at a time when there were
very few Doctors of Pharmacy employed outside of the traditional academic
environment of pharmacy schools
Developed the operational and economic foundations of a self-sustaining
Cardiovascular Clinical Pharmacology Research Program. This program has no
initial funding, but maintained a positive cash flow for 7/8 years and grew
from a staff of 1 to 10 FTE's. This program demonstrated a substantial
publication record from day one and ran from 1984 - 92
Initiated and fully-funded a post-doctoral Cardiovascular Clinical
Pharmacology Research Fellowship through the Division of Cardiology. One
of the few fellowships in the country offered to Doctor of Pharmacy
candidates outside the support from a pharmacy school.
Became the first Doctor of Pharmacy-trained individual to develop a
research program through a Positron Emission Tomography Facility.
Was the Principal Investigator of an American Heart Association grant-in-
aid from the Northeast Ohio Affiliate in 1985. This was the first grant
awarded to a Doctor of Pharmacy by that Affiliate.
Together with Mark A. Munger, Pharm.D., published a review of the
discrepancies between statutes of Pharmacy Practice and current
advancements being made in pharmacist-directed clinical care and research.
This publication led to numerous revisions of pharmacy practice acts with
specific reference applied to growth of the profession in general in the
areas of clinical care and research.
Became the first individual in the Department of Medicine to obtain funding
for Positron Emission Tomography Research at the PET Facility at the
University Hospitals of Cleveland.
Developed an incorporated Clinical Pharmacology Unit for Phase I, II, & III
clinical research called the Pharmaceutical Research Corporation, 1989
Founder, Collaborative Clinical Research, Inc., 1991, arguably the first
SMO model in the world.
UNIVERSITY HOSPITAL PUBLICATIONS - DRUG INFORMATION CENTER
Green JA, Evans RP. Captopril: a review of its pharmacology, efficacy and
side effects.
The University of Texas Health Science Center at San Antonio, Department of
Pharmacology, Drug Information Service, June 1981.
Green JA, Clementi WA. Verapamil: a review of its pharmacology, efficacy
and side
effects. The University of Texas Health Science Center at San Antonio,
Department of
Pharmacology and the Audie Murphy Veterans Administration Hospitals,
January 1982.
Green JA, Casto DT. The clinical utility of the mini-wright peak flow
meter in the
management of asthma. Department of Pharmacology, Drug Information
Service,
September 1981.
Green JA. Atenolol: Comparative efficacy and side effects of similar beta-
blockers.
University Hospitals of Cleveland, Department of Pharmacy Services, October
1982.
Green JA. Indomethacin Sustained Release. University Hospitals of
Cleveland,
Department of Pharmacy Services, September 1982.
Green JA, Salmi D. Flunisolide: Comparative efficacy and side effects with
beclo-
methasone diproprionate in the treatment of allergic rhinitis. University
Hospitals of
Cleveland, Department of Pharmacy Services, October 1982.
Green JA, Amin K. Pindolol: A review of its pharmacology, efficacy and
side effects.
University Hospitals of Cleveland, Department of Pharmacy Services,
November 1982.
James C, Green JA. Guanabenz: A review of its pharmacology efficacy and
side
effects. University Hospitals of Cleveland, Department of Pharmacy
Services, March
1983.
Schuler E, Green JA. Ranitidine: Pharmacology, efficacy, side effects and
adverse
Reactions compared to cimetidine. University Hospitals of Cleveland,
Department of
Pharmacy Services, March 1983.
Kover P, Green JA. Chymopapain: Review of its pharmacology, efficacy and
side
effects. University Hospitals of Cleveland, Department of Pharmacy
Services, June
1983.
Tschuddy J, Green JA. Comparison of intravenous diazepam and lorazepam in
the
Management of status epilepticus. University Hospitals of Cleveland,
Department of
Pharmacy Services, June 1983.
Dill H, Green JA. Comparison of topical miconazole and clotrimazole in the
manage-
ment of vaginal infections. University Hospitals of Cleveland, Department
of Pharmacy
Services, June 1983.
INVITED PRESENTATIONS
1. Acetaminophen intoxication and rationale for treatment.
Presented at the Texas Society of Hospital Pharmacists
Annual Meeting, San Antonio, March 1981.
2. Case Presentation: The elevation of serum digoxin
concentrations following quinine administration. Presented
at The American College of Physicians United States Air
Force Annual Meeting, San Antonio, March 1981.
3. Captopril: Review of its pharmacology, efficacy, and side
effects. Presented to the West Shore Pharmaceutical
Association, Cleveland, October 1982.
4. Clinical evaluation of transdermal nitroglycerin.
Presented at the Second Annual Meeting, Ohio Conference on
Clinical Pharmacy and Clinical Pharmacology, Cleveland,
October 1982.
5. Nifedipine-quinidine interaction. Presented at the Annual
Midyear Clinical Meeting, American Society of Hospital
Pharmacists, Los Angeles, December 1982.
6. Rational use of the slow channel calcium blockers.
Presented at the Association for Current Therapeutics,
Hillcrest Osteopathic Hospital, Cleveland, June 1983.
7. Clinical product evaluations of newly marketed preparations
as a basis for drug-product selection to hospital pharmacy
formularies. Presented at the Fourth Annual Meeting,
American College of Clinical Pharmacy, Washington, July
1983.
8. Use of Captopril in congestive heart failure: Physiologic
and pharmacological considerations presented to Akron Area
Hospital Association, Akron, October 1983.
9. Rational pharmacologic management of angina pectoris.
Presented to Family Medicine Department Grand Rounds, Case
Western Reserve University School of Medicine, Cleveland,
September 1983 and November 1984.
10. Pharmacokinetics of antidysrhythmics. Presented to the
Cleveland Society of Hospital Pharmacists, Cleveland,
November 1983.
11. Concentration-effect relationships in cardiovascular
pharmacology. Presented to the Division of Cardiology,
Millard Fillmore Hospital, Buffalo, March 1984.
12. Rational use of slow-channel calcium inhibitors. Presented
at the Fourth Annual Critical Care Symposium, Cleveland,
May 1984.
13. Dose-dependent hemodynamics of nifedipine in congestive
heart failure. Presented at the Fourth Annual Meeting,
Ohio Conference on Clinical Pharmacy and Clinical
Pharmacology, Cincinnati, October 1984.
14. Transdermal cardiovascular drug therapy. Presented at
Medical Grand Rounds, Lutheran Medical Center, Cleveland,
October 1984.
15. Characterization of the dose/concentration-dependent
hemodynamic effects of nifedipine in congestive heart
failure. Presented at the Research Institute Awards
Program, Sixth Annual Meeting of the American College of
Clinical Pharmacy, Orlando, July 1985.
16. Rationale of angiotensin converting enzyme inhibitors in
congestive heart failure. Presented at the 18th Annual
Seminar in Hospital Pharmacy, University of Toledo College
of Pharmacy, Toledo, November 1985.
17. Review of invasive hemodynamic assessment and
pharmacological management of congestive heart failure,
presented at Eli Lilly training sessions, Philadelphia,
Atlanta, and Indianapolis, 1985.
18. Use of inotropes in heart failure: Presented to Surgery and
Medical housestaff, Western Reserve Medical Center,
Youngstown, April 1986.
19. Use of angiotensin converting enzyme inhibitors in
hypertension and heart failure: Comparison of enalapril and
captopril, presented at the Second Annual Purdue Pharmacy
Alumni Seminar, West Lafayette, May 1986.
20. Transdermal drug delivery systems: controversies and
applications presented at Medical Grand Rounds, Robinson
Memorial Hospital, Ravenna, Ohio, May 1986.
21. Restrictive formulary systems and the emperor's new
clothes. Presented to Mid-Missouri Society of Hospital
Pharmacists, Columbia, July 1986.
22. Use of inotropic agents in critical care: Focus on
dobutamine. Presented at Medical Grand Rounds, Fairview
General Hospital, Cleveland, July 1986.
23. Review of the newer antidysrhythmics and their role in the
possible prevention of sudden death. Presented at the D.C.
Society of Hospital Pharmacists, Williamsburg, September
1986.
24. Pharmacologic review of the new antidysrhythmics.
Presented at the Northeast Society of Hospital Pharmacists,
Youngstown, September 1986.
25. Use of inotropic agents in critical care. Presented to the
Northeast Ohio Society of Hospital Pharmacists, Youngstown,
October 1986.
26. Visiting Professor Lecture, State University of New York at
Buffalo, Doctor of Pharmacy Graduate Program, "Pathogenesis
and therapeutic management of acute myocardial infarction",
Buffalo 1987.
27. Rational Pharmacologic Management of Angina Pectoris.
Presented at the Greater Cleveland Academy of Pharmacy,
Cleveland, March 1987.
28. Commentary: "On the Fringes", at the symposium entitled,
"Medicolegal Liability in Clinical Pharmacy Practice and
Research", at the Eighth Annual Meeting of the American
College of Clinical Pharmacy, Austin, July 1987.
29. Panel Roaster, Dr. Charles A. Walton appreciation dinner,
University of Texas Clinical Pharmacy Programs Reunion, San
Antonio, July 1987.
30. Pharmacologic Review of the New Antidysrhythmics.
Presented at the symposium entitled, "Recent advances in
the care of persons with cardiac and orthopedic problems",
Nursing Educational Services, Inc., Cleveland, August 1987.
31. Use of inotropes in the patient with the failing heart.
Presented at the North Central Society of Hospital
Pharmacists, Mansfield, September 1987.
32. Diagnosis and management of low output failure in the
critically ill. Presented at the California Society of
Hospital Pharmacists Seminar '87, Oakland, October 1987.
33. Pharmacologic approach to the patient with congestive heart
failure, presented to the Northwestern Pennsylvania Society
of Hospital Pharmacists, Erie, September 1987.
34. Use of vasoactive substance in congestive heart failure,
presented at the Michigan Society of Hospital Pharmacists
Annual Meeting, Detroit, October 1987.
35. Pharmacologic management of the patient with congestive
heart failure, presented to the Panhandle Society of
Hospital Pharmacists, Amarillo, November 1987.
36. The formulary system and the emperor's new clothes
presented to the Cleveland Society of Hospital Pharmacists,
Cleveland, October 1987.
37. Pharmacologic Approach to the Patient with Congestive Heart
Failure, presented to the Westshore Pharmaceutical
Association, Cleveland, November 1987.
38. Comparison of streptokinase, urokinase and tissue
plasminogen activator - Which Agent to Use? Presented as
part of the symposium entitled, "Use of tissue plasminogen
activator in the treatment of acute myocardial infarction,"
at the 22nd Annual American Society of Hospital Pharmacists
Midyear Clinical Meeting, Atlanta, December 1987.
39. Does the formulary impact on prescribing or does
prescribing impact on the formulary? Presented as part of
the symposium entitled, "Therapeutic Equivalency in the
Hospital Formulary", American Society of Hospital
Pharmacists Midyear Clinical Meeting, Atlanta, December
1987.
40. Roundtable Discussion, Thrombolytic therapy in Acute
Myocardial Infarction, sponsored by Hoescht, New York,
February 1988.
41. Point: Counterpoint - Streptokinase vs. TPA in Acute
Myocardial Infarction, presented to the Delaware Valley
Society of Hospital Pharmacists, Philadelphia, February
1988.
42. Clinical Pharmacology of the Beta-Blockers, presented at
Family Medicine Grand Rounds, Case Western Reserve
University and University Hospital of Cleveland, February
1988.
43. Thrombolytic therapy in acute myocardial infarction: Which
agent to use?, presented to the Chicago Metropolitan Health
Care Council, Chicago, March 1988.
44. Use of thrombolytic therapy in acute myocardial infarction,
presented at the 40th Annual Meeting of the Texas Society
of Hospital Pharmacists, Houston, April 1988.
45. Use of streptokinase in acute myocardial infarction,
presented at the Oregon Society of Hospital Pharmacists
Annual Meeting, Portland, May 1988.
46. Controversies and cost-effectiveness of thrombolytic
therapy, presented at continuing education symposium,
University of Nebraska Medical Center, Omaha, May 1988.
47. Review of the new antidysrhythmic agents and their role in
the treatment of patients predisposed to sudden death,
presented at Pennsylvania State University, State College,
May 1988.
48. Pharmacist-directed Cardiovascular Clinical Pharmacology
Research Program within a Department of Medicine, presented
at the Innovative Practice Forum as part of the 9th Annual
Meeting of the American College of Clinical Pharmacy,
Philadelphia, July 1988.
49. Review of thrombolytic therapy for acute myocardial
infarction, presented to Medical, Nursing & Pharmacy
Staffs, Allen Memorial Hospital, Oberlin, May 1988.
50. Thrombolytic therapy for acute myocardial infarction: Is
proof of mortality reduction critical to drug selection?
Presented at Mt. Sinai Medical Center, Cleveland, May 1988.
51. Legal implications of formulary decisions: Case Study -
Thrombolytic Agents, presented at the American Society of
Hospital Pharmacists 45th Annual Meeting San Francisco,
June 1988.
52. Clinical pharmacist involvement in directing a clinical
pharmacology research program and developmental presence in
a Positron Emission Tomography Facility, presented at
Purdue University School of Pharmacy and Pharmacal
Sciences, West Lafayette, September 1988.
53. Visiting Professor Lecture, Pathophysiology and management
acute myocardial infarction presented at the State
University of New York at Buffalo Doctor of Pharmacy
Program, Buffalo, August 1988.
54. Thrombolytic use in acute myocardial infarction - Which
agent to use?, presented at the El Paso area society of
hospital pharmacists, El Paso, Texas, October 1988.
55. Thrombolytic use in acute myocardial infarction - Is proof
of a reduction in mortality critical to drug selection?
Presented at the Indianapolis Area Society of Hospital
Pharmacists, Indianapolis, November 1988.
56. Review of thrombolytic agents in acute myocardial
infarction - A continuously changing database, presented at
the Council of Ohio Colleges of Pharmacy Continuing
Education Seminar, Columbus, November 1988.
57. Clinical pharmacist involvement in the research environment
of the future, presented at the Ohio Society of Hospital
Pharmacists Annual Meeting, Toledo, October 1988.
58. Review of the use of thrombolytic agents in acute
myocardial infarction, presented at the Dayton Area Society
of Hospital Pharmacists Annual Meeting, Toledo, October
1988.
59. Cost and efficacy analysis of thrombolytic therapy of acute
myocardial infarction, presented at the MedEcon Buying
Group Meeting, Buffalo, November 1988.
60. Current status of thrombolytic therapy of acute myocardial
infarction, presented at the Warren County Pharmaceutical
Association, Warren, Ohio September 1988.
61. Review of thrombolytic therapy for acute myocardial
infarction, presented at Amherst Hospital, Amherst,
September 1988.
62. Introduction to Positron Emission Tomography, presented at
Medical Grand Rounds, Case Western Reserve University
School of Medicine, October 1988.
63. Introduction to Positron Emission Tomography, presented at
St. Vincent's Medical Center Grand Rounds, October 1988.
64. Current status of thrombolytic therapy for acute myocardial
infarction, presented at the Long Island Society of
Hospital Pharmacists, Manhassett, November 1988.
65. Advances in cardiovascular pharmacotherapy, presented to
Hough Norwood Medical Staff, Cleveland, September 1988.
66. Advances in cardiovascular pharmacotherapy, presented at
the Cleveland Society of Hospital Pharmacists, Cleveland,
October 1988.
67. Pharmacokinetics & Pharmacodynamics of the beta-blockers,
HEARTLINE video presentation in conjunction with LSI
Communications, Philadelphia, October 1988.
68. Issues and controversies in thrombolytic therapy for acute
myocardial infarction, presented as part of the symposium
entitled, "The Aftermath of a P & T Decision - Pharmacist
Surveillance of Thrombolytic Use in Acute Myocardial
Infarction", 23rd Annual ASHP Midyear Clinical Meeting,
Dallas, December 1988.
69. Professional growth in Pharmacy and the Practice Act
Dilemma, presented to the Youngstown Area Society of
Hospital Pharmacists, February 1989.
70. Review of the antidysrhythmics, pharmacology and
therapeutic uses, presented to Pediatric Clinical
Pharmacology Fellows, Case Western Reserve University
School of Medicine, January 1989.
71. Panel Member and Discussant, Current status of thrombolytic
therapy use in the United States and Report of a National
Survey, presented to Upjohn & Beecham APSAC sales force,
Dallas, March 1989.
72. Pharmacologic approach to thrombolytic therapy, presented
at the symposium entitled, "Thrombolytic and anticoagulant
therapy", University of Southern California Educational
Seminar, Bally's Casino Resort, Las Vegas, March 1989.
73. Cost-effective considerations in thrombolytic therapy,
presented at the symposium entitled, "Thrombolytic and
anticoagulant therapy", University of Southern California
Educational Seminar, Bally's Casino Resort, Las Vegas,
March 1989.
74. Use of thrombolytic therapy in acute myocardial infarction,
efficacy and cost-effective considerations, presented at
Cedars Sinai Medical Center, Los Angeles, April 1989.
75. Current status of management of acute myocardial infarction
with thrombolytic therapy, presented at the United States
Air Force Annual Pharmacy Seminar, Wichita Falls, May 1989.
76. Use of Positron Emission Tomography in clinical medicine
and in drug development research, presented at the American
College of Clinical Pharmacy Regional Symposium,
Minneapolis, April 1989.
77. Pharmacist opportunities through participation in clinical
pharmacology research, presented to the Ohio Northern
College of Pharmacy, Faculty & Students, Ada, Ohio, April
1989.
78. The importance of homeostasis in cardiovascular disease,
presented as part of the seminar entitled, "Potassium
therapy: Current management and clinical implications",
Cleveland, June 1989.
79. Pharmacist involvement in clinical research: A personal
perspective, presented as part of the symposium entitled,
"Pharmacist Involvement in Clinical Research: Corporate,
Governmental & Regulatory Perspectives, Cleveland,
September 1989.
80. Thrombolytic therapy: Were do we stand today? Presented to
the NorMet Shard Services buying group in a debate of
streptokinase versus TPA, Newburg, New York, September
1989.
81. Calcium entry blocker classes & drug interactions,
presented as part of the symposium entitled, "Calcium entry
blockers: Pharmacology & Clinical Applications sponsored by
University of Missouri at Kansas City School of Pharmacy,
September 1989.
82. Clinical Practice Standards - Questions of Definition and
Liability, Panel Participant, Ohio Society of Hospital
Pharmacists Annual Meeting, Columbus, October 1989.
83. Use of Positron Emission Tomography in clinical medicine
and drug development research, presented at the American
College of Clinical Pharmacy Regional Symposium Series,
Pittsburgh, October 1989.
84. Nontraditional research practice of clinical pharmacy,
presented at the Chicagoland Clinical Conference, October
1989.
85. The nontraditional practice of clinical pharmacy:
Complications and considerations with respect to the
pharmacy practice acts, presented to the Nebraska Society
of Hospital Pharmacists, Omaha, October 1989.
86. Comparison of thrombolytic agents: Streptokinase, TPA and
APSAC, presented for the teleconference network of Texas in
conjunction with the Department of Pharmacology University
of Texas Health Science Center at San Antonio, October
1989.
87. New approaches to the management of heart failure,
presented at the Department of Family Medicine Fall CME
Course, Case Western Reserve University, November 1989.
88. Pharmacist involvement in the development of a Positron
Emission Tomography Facility, Research and Practice
Perspectives, presented at the seminar entitled, "Nuclear
(Radiologic) Pharmacy II: New frontiers and emerging
clinical opportunities for hospital-based services", at the
24th Annual ASHP Midyear Clinical Meeting, Atlanta,
December 1989.
89. The Pharmacist as a Principal Investigator, presented as
part of the seminar entitled, "Clinical pharmacists as
Principal Investigators: Legal and Professional
Implications", at the 24th Annual ASHP Midyear Clinical
Meeting, Atlanta, December 1989.
90. "Introduction to Positron Emission Tomography and its
potential use in the drug development process", presented
to Squibb Research Institute, Princeton, New Jersey,
November, 1989; Merck Sharpe & Dohme Research Labs, Iselin,
December 1989.
91. "Clinical & research utility of Positron Emission
Tomography in pharmacological assessment", presented to the
Departments of Pharmacy Practice, Pharmacology and
Pharmaceutics at the Philadelphia College of Pharmacy &
Science, Philadelphia, January 1990.
92. "Current issues in cardiovascular PET Research, presented
at the Cardiology Research Seminar at the University
Hospital of Pennsylvania, Philadelphia, January 1990.
93. "Clinical applications of cardiovascular Positron Emission
Tomography", presented at Cardiology Grand Rounds &
Clinical Conference, University Hospital of Pennsylvania,
Philadelphia, January 1990.
94. "Initial treatment of acute myocardial infarction with
thrombolytic therapy", presented at the Fifth Annual
Pharmacy Seminar - Critical Issues in Hospital Pharmacy &
Emergency Medicine, Tampa, January 1990.
95. "Pathophysiology, diagnosis & management of acute
myocardial infarction", visiting Professor Lecture at the
State University of New York at Buffalo School of Pharmacy,
January 1990.
96. "Use of Positron Emission Tomography in clinical cardiology
and drug development research, presented at combined
medical grand rounds, Timken Mercy Medical Center and the
Northeastern Ohio Universities College of Medicine, Canton,
February 1990.
97. Use of Positron Emission Tomography in the drug development
process, presented to Pfizer Pharmaceuticals, New York,
February 1990.
98. Program Moderator, "The Pharmacist as a Principal
Investigator", American Pharmaceutical Association Annual
Meeting, Washington, March 1990.
99. "Unresolved issues in the management of acute myocardial
infarction", presented as part of the symposium entitled,
"Therapeutic issues in cardiovascular and infectious
diseases", Richmond & Charleston, April 1990.
100. "Specialized investigations with lomefloxacin using
Positron Emission Tomography", presented at the
Lomefloxacin Investigators' Symposium, Miami, April 1990.
101. "Current status of thrombolytic therapy in acute myocardial
infarction", presented at Medicine 1990, An Annual Review
of Current Topics in Internal Medicine; Case Western
Reserve University, Cleveland, May 1990.
102. "Clinical Pharmacy Practice - Back to the Future",
presented at the symposium entitled, "Current trends in
clinical pharmacy", sponsored by Eli Lilly, Indianapolis,
April 1990.
103. Program Moderator for the symposium entitled, "Use of
Positron Emission Tomography (PET) in pathophysiologic
characterization, drug development and pharmacological
assessment", held at the 19th Annual Meeting of the
American College of Clinical Pharmacology, Las Vegas,
November 1990.
104. "Establishment of a self-supporting clinical pharmacology
research program within a school of medicine by a
pharmacist", presented at the Marshfield Clinic,
Marshfield, July 1990.
105. "Update and historical perspective on transdermal nitrate
therapy", sponsored by Summit Pharmaceuticals, Cleveland,
August 1990.
106. "Current status of thrombolytic therapy in acute myocardial
infarction", presented at the Washington State Society of
Hospital Pharmacists, Tacoma, October 1990.
107. "Historical perspectives on nitrate usage, past & current,
in the treatment of cardiovascular disease", presented at
the Greater Cleveland Academy of Pharmacy, October 1990
108. "Involvement of pharmacists in the clinical research
process", presented to Clinical Faculty & students, Ohio
Northern University School of Pharmacy, Ada, September
1990.
109. "Thrombolytic Therapy - What to do Now?" presented at the
Toledo College of Pharmacy, Toledo, September 1990.
110. "Beta-blockers in the '90s", presented to the Northeast
Ohio Academy of Pharmacy, Geneva, Ohio, September 1990.
111. "Development & implementation of a hospital-based clinical
research program", presented to Baltimore area pharmacists
& hospital administrators, Baltimore, October 1990.
112. "Pharmacists place in the clinical research process",
presented to the faculty & students of the University of
Maryland College of Pharmacy, Baltimore, October 1990.
113. "Liability & clinical pharmacy practice: Clinical & legal
aspects", presented to the Chesapeake College of Clinical
Pharmacy, Washington, October 1990.
114. "Historical perspective on nitrate use, past & current in
the treatment of cardiovascular disease", presented as part
of the seminar entitled, "Updates in the pharmacotherapy of
nitrates in ischemic heart disease", presented to hospital
& retail pharmacists, Cleveland, November 1990.
115. "The pharmacist as a principal investigator", presented at
the New England College of Clinical Pharmacy, Boston,
November 1990.
116. "Beta-blockers in the 90s: Focus on Betaxolol", presented
to the Jewish Pharmacists Association, Cleveland, November
1990.
117. "Recognition of nitrate tolerance and the current proper
use of transdermal nitroglycerin in the treatment of
ischemic heart disease", presented to the Medicine
housestaff, Mt. Sinai Medical Center, Cleveland, November
1990.
118. Quantitative effects of quinolone antibiotics on cerebral
blood flow, glucose and oxygen metabolism in health
volunteers using Positron Emission Tomography, presented at
the United States Food & Drug Administration Center for
Drug Evaluation & Research, January 1991.
119. "Use of Positron Emission Tomography in pathophysiologic
characterization and pharmacological assessment, presented
at Hartford Hospital, Hartford, January 1991.
120. "Focus of pharmacy towards clinical research", presented at
the Indiana Society of Hospital Pharmacists, Richmond, IN,
January 1991.
121. "Establishment of an independent, self-supporting
cardiovascular clinical pharmacology research program",
presented to cardiology staff & hospital administrators,
Loyola Medical Center, Chicago, January 1991.
122. "Use of Positron Emission Tomography in pathophysiologic
and pharmacologic assessment", presented at the Society of
Critical Care Medicine Annual Meeting, Pharmacology
Section, Washington, May 1991.
123. "Effects of quinolone antibiotics on cerebral blood flow
and metabolism", presented at the International Symposium
on Nuclear Imaging in Drug Discovery, Development and
Approval, Baltimore, June 1991.
124. "Management of the acute myocardial infarction patient",
presented at the Pharmacy Leadership Conference, Miami,
June 1991.
125. "Use of Positron Emission Tomography in Pharmacological
Assessment", presented at a seminar entitled, "Measurement
of drug disposition & effect by noninvasive means" at the
12th Annual Meeting of the American College of Clinical
Pharmacy, Minneapolis, August 1991.
126. "Use of thrombolytic therapy in acute myocardial
infarction", presented at Pharmacy Leadership Conference,
Scottsdale, September 1991.
127. "Treatment of acute myocardial infarction: Focus on
thrombolytic therapy", presented to the Central Society of
Hospital Pharmacists, Mansfield, Ohio, November 1991.
128. "Lessons learned from the thrombolytic therapy situation",
presented to students and faculty, Ohio Northern University
School of Pharmacy, Ada, February 1992.
129. "Roundtable discussion: How to become a recognized
principal investigator as a nonphysician in clinical
pharmacology research", American College of Clinical
Pharmacy 13th Annual Meeting, Toronto, August 1992.
130. "An entrepreneur's story of taking a clinical pharmacology
research program into the public sector", presented to
Edison Biotechnology luncheon and breakfast series,
Cleveland & Cincinnati, respectively, 1995.
131. Actual interventional clinical research in managed care
organizations: Two case studies, presented at IBC-sponsored
conference, Orlando, October 1997.
132. Presentation of the DataTRAK strategy when integrated with
a national network of sites, presented at a conference
entitled, "The Executive Retreat on Using Investigator
Networks (SMOs) to Impact Trial Performance.", Cape Cod,
August 1997.
133. Accelerating drug development through a standardized EDC
platform presented at an IBC Conference of Site Management
Organizations and CROs, Lake Buena Vista, December 3, 1998.
134. Panel Discussant, "The e-Healthcare Revolution: Capital
Connection Program Issues of Funding and Financing",
sponsored by eMarketWorld, Cleveland, Ohio August, 2000.
135. "The e-Clinical Trial: Fact or Fiction?" presented in
conjunction with Computer Sciences Corporation at the
symposium entitled, "Internet Solutions for Clinical
Trials" sponsored by International Clinical Management, New
York, New York, September 19-20, 2000.
136. "Maximize the Impact of the World Wide Web on Global
Clinical Trials", The Center for Business Intelligence, Web-
Based Clinical Trials Conference: Doubletree Hotel,
Philadelphia, PA, September 25 - 26, 2000
137. "Case studies on the successful implementation of DATATRAK
EDC( in worldwide clinical trials", presented at the
seminar entitled, "Case Report Forms: Design Standards and
New Solutions" sponsored by the Institute for International
Research, Walt Disney World Resort Hilton Hotel, Orlando,
Florida, September 25, 2000.
138. "From Traditional Data Capture Methodologies to Electronic
Data Capture - Compare Audit Trail Processes and
Procedures", presented as part of the seminar entitled,
"Auditing Clinical Trials Data - Electronic Data Capture -
Clinical Auditing Processes - FDA Inspections", Hilton
Orlando/Altamonte Springs Hotel - Orlando, Florida,
February 2001.
ABSTRACTS AND LETTERS
1. Guidry T, Clementi WA, Hunsaker L, Gonzalez L, Green JA,
Durst N. Constant rate of decline of serum phenytoin
concentrations following phenytoin intoxication in
hospitalized patients. Drug Intel Clin Pharm. 1982;16:473-
4.
2. Green JA, Clementi WA, Hunsaker L, Farringer J, Ebert S,
O'Rourke RA. Assessment of the variance between pre-dose
and post-dose serum quinidine concentrations. Drug Intel
Clin Pharm. 1982;16:473.
3. Sheppard AMM, Green JA, Pinkley W, Shapario S. Safety and
efficacy of ST 1615, a new antihypertensive agent. Clin
Res. 1982;30:839A.
4. Green JA, Farringer JA, Bufton MG, Durst NL, Clementi WA.
Clinical evaluations of newly marketed preparations as a
basis for drug-product selection to hospital pharmacy
formularies. Drug Intel Clin Pharm. 1983;17:450.
5. Glazier HS, Danziger LH, Green JA. Clinical pharmacists
and the under-educated physician. N Engl J Med.
1983;309:1257-8.
6. Green JA. Indomethacin sustained-release - author's reply.
Drug Intel Clin Pharm. 1985;9:682.
7. Mendel S, Green JA. Nitroglycerin I.V. tubing absorption.
Drug Intel Clin Pharm. 1985;19:467.
8. Kasmer RJ, Green JA, Nara AR, Chawla AK, Fleming G.
Comparable bioavailability of two preparations of
conventional-release procainamide hydrochloride. Drug
Intel Clin Pharm. 1986;20:451.
9. Green JA, Nara AR, Jarvis RC, Kasmer RJ, Pospisil R.
Effect of food on invasive hemodynamics in patients with
congestive heart failure. Drug Intel Clin Pharm.
1986;20:466.
10. Fong PA, Chawla AK, Green JA. Economic effect of opening a
restrictive formulary to one pharmacologic drug class: beta-
adrenergic blocking drugs. ASHP 43rd Annual Meeting.
Denver CO., June 1986.
11. Indecainide-disopyramide Research Group. Comparative
efficacy and safety of indecainide vs. disopyramide on
ventricular arrhythmias. Circulation. 1986;74:II-104.
12. Green JA, Nara AR, Jarvis RC, Pospisil R, Kasmer RJ,
Ziemniak J, Beck T. Effect of food ingestion on the
hemodynamic and pharmacokinetic profile of fenoldopam
mesylate in heart failure. Drug Intel Clin Pharm.
1987;21:12A.
13. Green JA, Nara AR, Jarvis RC, Pospisil R, Kasmer RJ, Beck
T. Invasive hemodynamic comparison of fenoldopam and
captopril in heart failure. Clin Pharmacol Ther.
1987;44:499-504.
14. Green JA and Munger MA. Why are clinical pharmacy
activities considered dispensable? Amer J Hosp Pharm.
1987;44:499-504.
15. Munger MA, Jarvis RC, Nair R, Kasmer RJ, Nara AR, Green JA.
Elucidation of the nifedipine-quinidine interaction. Drug
Intel Clin Pharm. 1987;21:12A-13A.
16. Kasmer RJ, Jarvis RC, Munger MA, Hricik D, Pospisil R, Nara
AR, Siminson M, Green JA. Single dose effects of ibopamine
HCl on renal function in patients with congestive heart
failure. Drug Intel Clin Pharm. 1987;21:4A.
17. Hricik DE, Appel RG, Siminson MS, Green JA, Smith R, Dunn
MJ. Effects of human atrial naturetic factor (ANF) in
patients with nephrotic syndrome (NS) and cirrhosis with
ascites. Kidney Int. 1987;31:273.
18. Hassan E, Green JA, Nara AR, Jarvis RC, Kasmer RJ, Pospisil
R. Usefulness of mixed venous oxygen saturation as a
therapeutic drug monitoring parameter. Drug Intel Clin
Pharm. 1987;21:21A.
19. Munger MA and Green JA. Practitioner-Director - Author's
reply. Amer J Hosp Pharm. 1987;44:1777.
20. Munger MA, Jarvis RC, Green JA, Nara AR, Pospisil RA,
Kasmer RJ. Assessment of hemodynamic tolerance from a 24-
hour intravenous infusion of fenoldopam mesylate in
congestive heart failure. Pharmacotherapy. 1988;8:119.
21. Green JA, Jarvis RC, Munger MA, Pospisil R, Nara AR, Kasmer
RJ. Constancy of deranged hemodynamics in congestive heart
failure despite right-heart catheterization.
Pharmacotherapy. 1988;8:119.
22. Bednarczyk EM, Panacek EA, Leisure G, Munger MA, Green JA,
Miraldi F, Rutherford WF. Reduction in cerebral blood flow
during hyperventilation: an evaluation by positron emission
tomography. Pharmacotherapy. 1988;8:134.
23. Green JA, Miraldi F, Leisure GP, Nelson D, Berridge M,
Grinblatt M. Measurement of renal blood flow using
positron emission tomography. Pharmacotherapy.
1988;8:128.
24. Munger MA, White EB, Panacek EA, Bednarczyk EM, Rutherford
WF, Nara AR, Green JA. Comparative, acute blood pressure
reduction of intravenous fenoldopam mesylate vs. sodium
nitroprusside in patients with severe hypertension. AJH.
1988;1:6A.
25. Rutherford WF, Panacek EA, Green JA, Bednarczyk EM, Munger
MA, Leisure GP, Miraldi F, Fisher CJ. Does conjunctival
oxygen tension predict cerebral blood flow in normal humans
during eucapnia and hypocapnia? Ann Emerg Med.
1988;17:396-7.
26. Munger MA, White EB, Panacek E, Bednarczyk EM, Rutherford
WF, Nara AR, Green JA. Comparative acute blood pressure
reduction of intravenous fenoldopam mesylate vs. sodium
nitroprusside in patients with severe hypertension. Ann
Emerg Med. 1988;17:441-2.
27. Bednarczyk EM, Munger MA, Panacek EA, Rutherford WF, Nara
AR, Green JA. Intravenous fenoldopam mesylate in the
management of severe systemic hypertension.
Pharmacotherapy. 1989;9:175.
28. Green JA, Schleman M, Munger MA, Nara AR, Pospisil RA,
Goldberg P, Kasmer RJ. Invasive pharmacodynamic
characterization of combined ibopamine and calcium
antagonist therapy for congestive heart failure. J Clin
Pharmacol. 1989;29:861.
29. Bednarczyk EM, Miraldi F, Nelson D, Leisure GP, Adler L,
Berridge M, Panacek E, Green JA. Comparative assessment of
temafloxacin, ciprofloxacin or placebo on cerebral blood
flow, glucose and oxygen metabolism in health subjects via
positron emission tomography. Clin Pharmacol Ther.
1990;47:147.
30. Green JA, Bednarczyk EM, Miraldi F, Leisure GP, Nelson D,
Reed RC, Adler L, Berridge M, Panacek E. Change in
cerebral blood flow from initial to follow-up study in
volunteers using positron emission tomography. Clin
Pharmacol Ther. 1990;47:136.
31. Gardner SF, Green JA, Bednarczyk EM, Leisure GP, Adler L,
Nelson D, Miraldi F. Inter & intrasubject variability in
cerebral blood flow and glucose metabolism in health
volunteers obtained by positron emission tomography.
Pharmacotherapy. 1990;10:254.
32. Bednarczyk EM, Miraldi F, Nelson D, Little D, Leisure GP,
Adler L, Berridge M, Panacek E, Green JA. Comparative
assessment of the effect of lomefloxacin, ciprofloxacin or
placebo on cerebral blood flow, glucose and oxygen
metabolism in healthy subjects via positron emission
tomography. Pharmacotherapy. 1990;10:234.
33. Munger MA, Chance M, Nair RN, Prescott AW, Nara AR,
Simonson MS, Green JA, Posvar EL. Evaluation of quinapril
on regional blood flow and cardiac function in patients
with congestive heart failure. J Clin Pharmacol.
1990;30:833.
34. Bednarczyk EM, Elliott WJ, Murphy MB, Panacek EA, Gonzalez
FM, Rutherford W, Weed SG, Goodman BL, Nara AR, Weikart C,
Semchuk W, Green JA. Evaluation of an extended infusion of
fenoldopam mesylate vs. sodium nitroprusside in the
management of severe hypertension. J Clin Pharmacol.
1990;30:839.
35. Gardner SF, Green JA, Miraldi F, Bednarczyk EM, Nelson D,
Leisure GP. Positron emission tomographic evaluation of
the effect of fleroxacin on cerebral blood flow and
metabolism in healthy volunteers treated orally with
fleroxacin. Eur J Clin Micro Inf Dis. 1991; special
proceedings issue: 227.
36. Green JA, Bednarczyk EM, Nelson D, Gardner SF, Reed RC,
Miraldi F. Biologic fluctuation in cerebral blood flow and
glucose metabolism in healthy volunteers. Clin Pharmacol
Ther. 1991;49:184.
37. Bednarczyk EM, Miraldi F, Nelson D, Little D, Leisure GP,
Adler L, Berridge M, Green JA. Assessment of the effect of
ciprofloxacin vs. nalidixic acid on cerebral blood flow and
metabolism in healthy subjects via positron emission
tomography. Clin Pharmacol Ther. 1991;49:200.
38. Gardner SF, Green JA, Bednarczyk EM, Miraldi F, Nelson D,
Leisure GP, Landemier BJ. Evaluation of the effect of
fleroxacin on cerebral blood flow and metabolism in normal
healthy volunteers as assessed by positron emission
tomography. J Clin Pharmacol. 1990;30:833.
39. Nelson AD, Green JA, Bednarczyk EM, Leisure GP, Landemier
BJ, Muswick GJ, Ellert E, Muzic RF, Adler LP, Manfredi LP,
Miraldi F. Intra-patient and interpatient variability in
PET brain flow studies using the water bolus technique. J
Nucl Med. 1991; : .
40. Green JA, Weikart C, Lebsack M, Bednarczyk EM, Nelson AD,
Miraldi F. A study of the effects of enoxacin on cerebral
blood flow and metabolism. Pharmacotherapy. 1991;11:267.
41. Gardner SF, Lazarus H, Bednarczyk EM, Green JA. Use of
positron emission tomography to assess cyclophosphamide-
induced cardiomyopathy in bone marrow transplant patients.
Pharmacotherapy. 1991;11:277.
42. Green JA, Bednarczyk EM, Miraldi F, Gardner SF, Nelson AD,
Leisure GP. Reduction in cerebral glucose metabolism
caused by quinolone administration in healthy volunteers.
J Nucl Med Biol. 1991;19:126.
43. Bednarczyk EM, Miraldi F, Nelson AD, Leisure GP, Adler L,
Berridge MS, Green JA. Assessment of the variability of
blood flow and metabolism measured via PET in healthy
volunteers. J Nucl Med Biol. 1991;19:126.
44. Leisure GP, Green JA, Giboney S. Time clocks in health-
care institutions. Am J Hosp Pharm. 1991;48:464.
45. Bednarczyk EM, Reed RC, Remler B, Adler L, Fox A, Green JA,
Nelson DA, Daroff RB, Miraldi F. Evaluation of global
cerebral blood flow, blood volume and oxygen metabolism in
patients with migraine headache. Pharmacotherapy.
1992;12:264.
ACKNOWLEDGEMENTS
Hassan, Miller D. Toxicity and elimination of trazodone after overdose.
Clin Pharm. 1985;4:97-100.
Hassan E, Roffman DS, Applefeld MM. Value of mixed venous oxygen
saturation as a therapeutic indicator in the treatment of advanced
congestive heart failure. Am Heart J. 1987;113:743-9.
Editorial Advisory Board, Contemporary Management of Atrial Fibrillation
and Flutter, A Continuing Education Primer, 1991.
MANUSCRIPTS
1. Green JA. Efficacy of 10 units/ml vs. 100 units/ml of
heparin and maintaining patency of heparin locks. Conner
CS, ed. Drug-Dex Publications, Englewood, CO. Micromedex,
Inc., January 1982.
2. Green JA. Efficacy of warfarin in the treatment of small
cell carcinoma of the lung. Conner CS, ed. Drug-Dex
Publications, Englewood, CO. Micromedex Inc., January
1982.
3. Green JA. Effect of lithium on platelet function. Conner
CS, ed. Drug-Dex Publications, Englewood, CO. Micromedex
Inc., March 1982.
4. Green JA. Use of phenothiazines and tricyclic
antidepressants in the treatment of diabetic neuropathic
pain. Conner CS, ed. Drug-Dex Publications, Englewood, CO.
Micromedex, Inc. March 1982.
5. Green JA and Clementi WA. Decrease in theophylline
clearance after the administration of erythromycin to a
patient with obstructive lung disease. Drug Intel Clin
Pharm. 1983;17:370-2.
6. Green JA, Clementi WA, Porter C, Stigelman WH. Nifedipine-
quinidine interaction. Clin Pharm. 1983;2:461-5.
7. Farringer JA, Green JA, O'Rourke RA, Linn WA, Clementi WA.
Nifedipine-induced alterations in serum quinidine
concentrations. Am Heart J. 1984;108:1570-2.
8. Green JA. Indomethacin sustained release? Drug Intel Clin
Pharm. 1984;18:1004-7.
9. Green JA, Chawla AK, Fong PA. Evaluating a restrictive
formulary system by assessing nonformulary drug requests.
Amer J Hosp Pharm. 1985;42:1537-41.
10. Green JA, Clementi WA, Farringer JA, Bufton M, Mosier R,
Durst N. Experience with intrainstitutional clinical
evaluations of newly marketed preparations as a basis for
drug product selection to hospital pharmacy formularies.
Drug Intel Clin Pharm. 1985;20:69-73.
11. Kasmer RJ, Nara AR, Green JA, Chawla AK, Fleming GM.
Comparable steady-state bioavailability of two preparations
of conventional-release procainamide hydrochloride. Drug
Intel Clin Pharm. 1987;21:183-6.
12. Green JA. The formulary system and the emperor's new
clothes. Am J Hosp Pharm. 1986;43:2830-4.
13. Green JA, Nara AR, Gengo FM. Characterization of the
dose/concentration dependent hemodynamic effects of
nifedipine in heart failure. J Clin Pharmacol.
1987;27:574-81.
14. Munger MA and Green JA. The Practitioner-Director. Amer J
Hosp Pharm. 1987;44:592-3.
15. Jarvis RC, Green JA, Nara AR, Pospisil R, Kasmer RJ. The
effects of food ingestion on hemodynamics in chronic
congestive heart failure. Crit Care Med. 1988;16:491-4.
16. Green JA. Hemodynamic effects of nifedipine in congestive
heart failure. Hosp Ther. 1987;104-110.
17. Munger MA and Green JA. Professional liability for
pharmacists: A focus on pharmacy practice acts. Drug Intel
Clin Pharm. 1988;22:886-8.
18. Green JA and Munger MA. On the fringes. Pharmacotherapy.
1989;9:95-8.
19. Hassan E, Green JA, Nara AR, Jarvis RC, Kasmer RJ, Pospisil
R. Continuous monitoring of mixed venous oxygen saturation
as an indication of pharmacologic intervention. Chest.
1989;95:406-9.
20. Barbarash RA, Bauman J, Gonzalez E, Green JA, Hopkins L,
Meister F. Roundtable on thrombolytic therapy. US
Pharmacist. 1988;13:H31-H44.
21. Green JA. Thrombolysis for acute myocardial infarction: Is
proof of a reduction in mortality critical to drug
selection? Clin Pharm. 1988;7:473-7.
22. Rutherford WF, Panacek EA, Griffith K, Green JA, Munger MA,
Bednarczyk EM, Miraldi F, Fisher CJ. Prediction of
changing cerebral blood flow by use of the conjunctival
oxygen tension/arterial oxygen tension index. Crit Care
Med. 1989;23:1328-32.
23. Bednarczyk EM, Sherlock S, Farah M, Green JA. Anaphylactic
reaction to streptokinase: A case report and a review of
the literature. Drug Intel Clin Pharm. 1989;23:869-72.
24. Munger MA, Jarvis RC, Nara AR, Kasmer RJ, Nair R, Green JA.
Elucidation of the nifedipine-quinidine interaction. Clin
Pharmacol Ther. 1989;45:411-6.
25. Green JA. Drug-use evaluation of thrombolytic agents - A
challenge for pharmacists. Amer J Hosp Pharm.
1988;45:2192-4.
26. Bednarczyk EM, White WB, Munger MA, Gonzalez FM, Panacek
EA, Weed SG, Rutherford WF, Nara AR, Green JA. Comparative
acute blood pressure reduction from intravenous fenoldopam
in patients with severe hypertension. Am J Cardiol.
1989;63:993-6.
27. Munger MA, Benotti J, Green JA, Jarvis RC, Nara AR,
Pospisil RA, Kasmer RJ. Assessment of tolerance from a 24-
hour intravenous infusion of fenoldopam mesylate in
congestive heart failure. Am J Cardiol. 1990;65:206-10.
28. Green JA, Munger MA, Reed RC, Bednarczyk EM. Pharmacy
Practice Acts: Are they stifling professional growth?
American Pharmacy. 1989;NS29:754-6.
29. Kasmer RJ, Cutler RE, Jarvis RC, Munger MA, Hricik D, Nara
AR, Goldberg P, Green JA. Single-dose effects of ibopamine
HCl on renal function in patients with congestive heart
failure. Br J Clin Pharmacol. 1990;30:485-9.
30. Bednarczyk EM, Panacek EA, Leisure GP, Munger MA, Miraldi
F, Rutherford WF, Green JA. Hyperventilation-induced
reduction in cerebral blood flow: Assessment by positron
emission tomography. DICP Ann Pharmacother. 1990;24:456-
60.
31. Grasela T and Green JA. A national survey of thrombolytic
prescribing patterns in the United States.
Pharmacotherapy. 1990;10(1):35-41.
32. Munger MA, Rutherford WF, Hakki AI, Gonzalez FM, Bednarczyk
EM, Emmanuel G, Weed SG, Green JA. Assessment of
intravenous fenoldopam mesylate in the management of severe
systemic hypertension. Crit Care Med. 1990;18:502-4.
33. Green JA. The health care professional of the future -
Function based upon competence. DICP Ann Pharmacother.
1991;25:205-8.
34. Green JA. Risks vs. benefits: The alteplase experience.
Am J Hosp Pharm. 1989;46(suppl 2):S15-S19.
35. Green JA and Munger MA. Pharmacy practice acts -
Discrepancy. Ohio Pharmacist. 1989;38:20-2.
36. Bednarczyk EM, Green JA, Miraldi F, Nelson D, Little D,
Adler L, Berridge M, Panacek E. Comparative assessment of
the effect of temafloxacin, ciprofloxacin, or placebo on
cerebral blood flow, glucose and oxygen metabolism, in
health subjects via positron emission tomography. Clin
Pharmacol Ther. 1991;50:165-71.
37. Gardner SF, Green JA, Bednarczyk EM, Nelson AD, Leisure GP,
Landemier BJ, Miraldi F. An assessment of cerebral blood
flow and metabolism following fleroxacin therapy. J Clin
Pharmacol. 1991;31:151-7.
38. Blanchett DG, Green JA, Nara AR, Pospisil R, Jarvis RC,
Kasmer RJ, Boyle DA, Cyronak MJ, Corder CN. The effect of
food on pharmacokinetics and pharmacodynamics of fenoldopam
in class III heart failure. Clin Pharmacol Ther.
1991;49:449-56.
39. Munger MA, Green JA, Nara AR, Pospisil RA, Kasmer RJ,
Schleman M. Invasive pharmacodynamic characterization of
combined ibopamine and calcium antagonist therapy for
congestive heart failure. Eur J Clin Pharmacol.
40. Munger MA, Chance M, Nair R, Prescott AW, Nara AR, Simonson
MS, Green JA, Posvar EL. Evaluation of quinapril on
regional blood flow and cardiac function in patients with
congestive heart failure. J Clin Pharmacol. 1992;32:70-6.
41. Bednarczyk EM, Green JA, Nelson AD, Leisure GP, Little D,
Adler L, Berridge MS, Panacek EA, Miraldi F. Comparative
assessment of the effect of lomefloxacin, ciprofloxacin or
placebo on cerebral blood flow, glucose and oxygen
metabolism in healthy subjects via positron emission
tomography. Pharmacotherapy. 1992;12(5):369-75.
42. Gardner SF, Green JA, Bednarczyk EM, Farnett L, Miraldi F.
Principles and clinical applications of positron emission
tomography. Am J Hosp Pharm. 1992;49:1499-506.
43. Pilmer BL, Green JA, Panacek EA, Elliot WJ, Murphy MB,
Rutherford W, Nara AR. Fenoldopam mesylate versus sodium
nitroprusside in the acute management of severe systemic
hypertension. J Clin Pharmacol. 1993;33:549-553.
44. Gardner SF, Lazarus HM, Bednarczyk EM, Creger RJ, Miraldi
FD, Leisure G, Green JA. High-dose cyclophosphamide-
induced myocardial damage during BMT: assessment by
positron emission tomography. Bone Marrow Transplant.
1993;12:139-44.
45. Bednarczyk EM, Furniss SM, Green JA, Munger MA. Evaluation
of the indomethacin-nitroglycerin interaction with positron
emission tomography. J Cardiovas Pharmacol. 1997;30:731-
3.
46. Green JA. Changing the face of pre-market clinical
research. Med Industry Information Rep. 1997;2:32-6.
TEXTBOOK CONTRIBUTIONS
1. Green JA. Rational use of therapeutic drug monitoring, in
Analytic Toxicology, Sunshine I., editor. CRC Press, Inc.
Boca Raton, 1985.
2. Gengo FM and Green JA. Beta-blocker antagonists, in
Applied Pharmacokinetics. Evans W, Schentag JJ and Jusko
W. editors. Applied Therapeutics, Inc., Spokane, Second
book listing, 1986.
3. Green JA and Botti RE. Cardiovascular Clinical
Pharmacology, in Glenn's Textbook of Cardiovascular
Surgery. Appleton & Lange, 1991. pp. 1367-78.
Contact this candidate